News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sapphire Therapeutics, Inc. Licenses Ghrelin Mimetic From Novo Nordisk A/S (NVO)


9/19/2006 10:46:55 AM

BRIDGEWATER, NJ -- (MARKET WIRE) -- September 19, 2006 -- Sapphire Therapeutics, Inc., a private biopharmaceutical company that inlicenses compounds acting within the ghrelin pathway and develops them as treatments for metabolic and oncologic diseases, has licensed a highly potent and selective small-molecule ghrelin mimetic, ipamorelin, from Novo Nordisk.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES